Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Scientists find twisting magnetic waves on the sun. Could this help solve a huge solar mystery? - 2Vote In favor of Your Favored Shimmering Water
- 3New findings suggest atmosphere could exist on exoplanet TOI-561b
- 4The most effective method to Guarantee Scholastic Honesty in Web-based Degrees
- 5Doctor's orders? ‘Belly laugh at least two to five days a week'
- Flu is rising rapidly, driven by a new variant. Here's what to know
- Manual for Notorious Fragrances: Immortal Aromas
- A definitive Burger Confrontation: Which One Rules?
- Heat Wave Fuels Massive Wildfire In Australia
- 6 Objections for an Ocean side Wedding
- Foods with healthy-sounding buzzwords could be hiding added sugar in plain sight
- Advocacy groups react after Mattel introduces 1st Barbie doll with autism
- Flu cases are spiking earlier than usual. What you need to know.
- The most effective method to Really Adjust Hypothesis and Practice in Your Brain science Studies
